Table 2.

Univariate and multivariate analyses of standard parameters and plexin B1 in relation to disease-free survival

ParameterAll patients (N = 119)ER-positive patients only (n = 79)
Univariate analysisPnPn
    Age (≤50 vs >50 y)0.312959 vs 600.273144 vs 35
    Tumor size (>2 vs ≤2 cm)0.023259 vs 600.074739 vs 40
    Lymph node (positive vs negative)0.130851 vs 660.113939 vs 39
    Molecular grading (above vs below median proliferation)0.039560 vs 590.087239 vs 40
    ER status (negative vs positive)0.165340 vs 79n.a.n.a.
    HER2 mRNA (Affymetrix value >4,500 vs ≤4,500)0.069023 vs 960.01219 vs 70
    Plexin B1 mRNA median (below vs above median Affymetrix-value in each individual sample group)0.017360 vs 590.052640 vs 39
    Plexin B1 mRNA (Affymetrix value ≤500 vs >500)0.006265 vs 540.010727 vs 52
Multivariate Cox regressionPHazard ratio (95% CI)PHazard ratio (95% CI)
    Tumor size (≤2 vs >2 cm)0.0170.35 (0.15-0.83)0.0260.25 (0.08-0.85)
    Plexin B1 mRNA (Affymetrix-value >500 vs ≤500)0.0320.40 (0.17-0.93)0.0220.31 (0.12-0.85)
    HER2 mRNA (Affymetrix value >4,500 vs ≤4,500)0.0482.41 (1.01-5.76)0.004*6.12 (1.81-20.7)*
  • * High hazard ratio based on only 9 (11.4%) HER2-expressing patients in this ER-positive subgroup.